

Synthesis and Antimicrobial Study of Pyrimidinone Substituted 4(3H)-Quinazolinone Derivatives

Natvar A Sojitra¹, Rajesh K Patel², Ritu B Dixit² and Bharat C Dixit^{1*}

¹Chemistry Department, V. P. & R. P. T. P. Science College, Affiliated to Sardar Patel University, Gujarat, India

²Ashok & Rita Patel Institute of Integrated Studies and Research in Biotechnology and Allied Sciences, Gujarat, India

³Department of Life Sciences, Hemchandracharya North Gujarat University, Gujarat, India

Abstract

A series of structurally diverse and newly designed pyrimidinone substituted 4(3H)-Quinazolinone derivatives **6a–6j** were synthesized in a simple and facile manner under both conventional and microwave heating conditions. Entitled compounds **6a–6j** were synthesized using *N*-acylanthranilic acid derivatives **1a–1j** and hydrazinylbenzenesulfonamide **2** as a key starting materials, which under goes hierarchy of the reactions *via* different intermediate stages; quinazolinone derivatives **3a–3j** and hydrazonoquinazolinone derivatives **5a–5j**. All the synthesized compounds are in good amount of yield. The structure of entitled compounds have been evaluated on the basis of various spectroscopic techniques and analytical methods as well as, all the synthesized compounds were subjected to *in vitro* antibacterial activities. Some of the compounds displayed moderate to good *in vitro* antimicrobial activity by broth micro dilution method against pathogenic bacteria (*S. aureus*, *B. subtilis*, *B. megaterium*, *E. coli*, *P. vulgaris*, *P. aeruginosa*) species.

Keywords: Quinazolinone; Pyrimidinone; Antimicrobial activity; Microwave heating

Introduction

Heterocyclic scaffold has been under discovery due to their considerable therapeutic and medicinal importance. One of such heterocycles 2-pyrimidinone, while not naturally occurring, are receiving increased attention because of their wide-ranging biological activity like, an efficient inhibitor of DNA synthesis in *E. coli*, inhibitors of the enzyme *cytidinedeaminase*, and as metaphase inhibitors. Such pyrimidinone derivatives and the pharmaceutical acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, thereby, being useful in treating cardiovascular disease caused by binding angiotensin II to its receptor. Antitumor activity of pyrimidinone derivatives have shown statistically significant synergism with cyclophosphamide (CY) against antitumor / P388 leukemia etc. [1-7]. They have also shown anticancer [8,9], potent TF-FVIIa inhibitors [10] and inhibition of C5-cytosine DNA methyltransferases [11] activities.

In addition to that, quinazolinone and its derivatives comprise an important class of heterocyclic molecules due to their broad spectrum application in medicinal and pharmaceutical chemistry such as analgesic [12], antimicrobial and antitubercular [13,14], antitumor [15], anticancer [16], anti-inflammatory [17], anticonvulsant [18], antimalarial and antihistamine [19].

Moreover, there are many reports regarding synthesis of pyrimidinone derivatives [20,21] but no reports are available in which pyrimidinone is substituted at 3rd position of quinazolinone through hydrazono benzenesulfonamide linkage. Looking to the aforementioned literature and our ongoing research in the field of quinazolinone derivatization [22,23], we reports here synthesis of various pyrimidinone substituted quinazolinone derivatives linked through hydrazono benzenesulfonamide, of that some of the compounds showed good to moderate antimicrobial activity.

Experimental Section

Material and measurements

All the chemicals were purchased from Spectro chem. Ltd. (Mumbai,

India) and were used without further purification. Solvents employed were distilled, purified and dried by standard procedures prior to use [24]. Melting points of the synthesized compounds were determined in open capillary tube method and are uncorrected. Reactions were monitored by thin-layer chromatography (TLC on aluminium plates coated with silica gel 60 F₂₅₄, 0.25 mm thickness purchased from E. Merck Ltd., Mumbai-India). The mobile phase was chloroform and methanol (9:1), and detection of the components was done under UV light or explore in Iodine chamber. Infrared (IR) spectra were recorded as potassium bromide pellets using a Shimadzu 8501 Fourier transform infrared (FTIR) Spectrophotometer. ¹H and ¹³C NMR spectra were recorded on a Bruker AVANCE II 400-MHz NMR spectrometer (Bruker Corporation, Billerica, MA, USA), with chemical shift in ppm downfield from TMS as an internal reference and DMSO-*d*₆ used as solvent. Carbon, hydrogen and nitrogen elemental analysis were estimated by PerkinElmer 2400-II CHN elemental analyzer, USA. The electro-spray ionization mass spectra in positive mode were recorded on a Shimadzu LC-MS 2010 eV mass spectrophotometer using acetonitrile. All the microwave assisted reactions were carried out at atmospheric pressure using a multimode microwave reactor (Scientific Microwave Synthesis System, Model: Cata-R, Catalyst™ Systems, Pune-India) with attachment of glass vessel prolonged by a reflux condenser with constant stirring, whereby microwaves were generated by magnetron at a frequency of 2450 MHz having an output energy range of 140 to 700 Watts, and the temperature was monitored with an external flexible probe.

***Corresponding author:** Bharat C Dixit, Chemistry Department, V. P. & R. P. T. P. Science College, Affiliated to Sardar Patel University, VallabhVidyangar– 388 120, Anand, Gujarat, India, E-mail: dixits20002003@yahoo.co.in

Received May 03, 2013; Accepted July 26, 2013; Published July 29, 2013

Citation: Sojitra NA, Patel RK, Dixit RB, Dixit BC (2013) Synthesis and Antimicrobial Study of Pyrimidinone Substituted 4(3H)-Quinazolinone Derivatives. Organic Chem Curr Res 2: 118. doi:[10.4172/2161-0401.1000118](http://dx.doi.org/10.4172/2161-0401.1000118)

Copyright: © 2013 Sojitra NA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General procedure for the synthesis of 4-amino-N-(2-methyl/aryl-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide derivatives(3a-3j)

Compounds 3a–3j were prepared according to the reported method [22,23]. The possible synthetic route is given in Scheme 1.

3-yl)benzenesulfonamide (5b) m.p. 145–147°C, ESI MS (m/z): 520.1,

522.3 [M]⁺.

4-[N²-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6,8-dibromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamide (5c) m.p. 172–174°C, ESI MS (m/z): 597.2, 599.1, 601.3 [M]⁺.

4-[N²-(1-Acetyl-2-oxopropylidene)hydrazino]-N-(2-methyl-6-nitro-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (5d) m.p. 189–190°C, ESI MS (m/z): 549.4 [M+H]⁺.

4-Amino-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide (3a) mp 217–218°C. ESI MS (m/z): 330.8 [M+H]⁺.

4-Amino-N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)

benzenesulfonamide (3b) mp 187–189°C. ESI MS (m/z): 409.2, 411.3 [M]⁺.

4-Amino-N-(6,8-dibromo-2-methyl-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide (3c) mp 212–214°C. ESI MS (m/z): 488.4, 490.4, 492.4 [M]⁺.

4-Amino-N-(6-nitro-4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (3d) mp 206–209°C. ESI MS (m/z): 438.2 [M+H]⁺.


4-Amino-N-(4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (3e) mp 166–168°C. ESI MS (m/z): 393.4 [M+H]⁺.

4-Amino-N-(6-bromo-4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (3f) mp 214–217°C. ESI MS (m/z): 471.3, 473.3 [M]⁺.

4-Amino-N-(6,8-dibromo-4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (3g) mp 219–221°C. ESI MS (m/z): 548.3, 550.3, 552.3 [M]⁺.

4-Amino-N-[2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl]benzenesulfonamide (3h) mp 175–179°C. ESI MS (m/z): 426.9, 428.9 [M]⁺.

4-Amino-N-[6-bromo-2-(4-chlorophenyl)-4-oxoquinazolin-



Scheme 1: Proposed synthetic route for the preparation of pyrimidinone substituted 4(3H)-quinazolinone derivatives compound (6a-6j).

3(4H)-yl]benzene-sulfonamide (3i)mp 186-187°C. ESI MS (m/z): 503.8, 505.8, 507.8 [M]⁺.

4-Amino-N-[6,8-dibromo-2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl]benzene

sulfonamide (3j)mp 183-184°C. ESI MS (m/z): 582.5, 584.5, 586.5, 588.5 [M]⁺.

General procedure for the diazotization of 4-amino-N-(2-methyl/aryl-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide derivatives(4a-4j)

The diazotized derivatives **4a-4j** were prepared by following the reported method [23,25]. Schematic diagram to produce diazotized compounds **4a-4j** are shown in Scheme 1. The reaction mass was cooled at 0-5°C for 1 hours and was directly used for the next step.

General procedure for the synthesis of hydrazono derivatives of compounds 4a-4j using acetyl acetone as an active methylene compound (5a-5j)

Hydrazonoquinazolinone compounds **5a-5j** were prepared by following the reported method [23,26]. The synthetic route is shown in Scheme 1.

4-[N'-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(2-methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (5a) m.p. 167-168°C, ESI MS (m/z): 442.2 [M+H]⁺.

4-[N'-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6-bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (5e) m.p. 164-166°C, ESI MS (m/z): 504.2 [M+H]⁺.

4-[N'-(1-Acetyl-2-oxopropylidene)hydrazino]-N-(6-bromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide (5f) m.p. 183-184°C, ESI MS (m/z): 582.3, 584.4 [M]⁺.

4-[N'-(1-Acetyl-2-oxo-propylidene)hydrazino]-N-(6,8-dibromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide (5g) m.p. 193-195°C, ESI MS (m/z): 660.0, 662.2, 663.9 [M]⁺.

4-[N'-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[6-bromo-2-(4-chloro-phenyl)-4-oxo-4H-quinazolin-3-yl]benzenesulfonamide (5h) m.p. 178-180°C, ESI MS (m/z): 538.0, 539.8 [M]⁺.

4-[N'-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[6-bromo-2-(4-chlorophenyl)-4-oxo-4H-quinazolin-3-yl]benzenesulfonamide (5i) m.p. 203-204°C, ESI MS (m/z): 616.2, 617.9, 620.0 [M]⁺.

4-[N'-(1-Acetyl-2-oxopropylidene)hydrazino]-N-[6,8-dibromo-2-(4-chlorophenyl)-4-oxo-4H-quinazolin-3-yl]benzenesulfonamide (5j) m.p. 214-215°C, ESI MS (m/z): 693.8, 695.7, 697.7, 699.9 [M]⁺.

Synthesis of pyrimidinone substituted quinazolinone derivatives 6a-6j

It was prepared using the appropriate hydrazono compound **5a-5j**(0.01 mol) and urea (0.015) in 40 ml absolute ethanol using anhydrous sodium acetate as a catalyst (0.001 mol). The reaction mixture was heated under reflux for 5 hours. Completion of reaction was checked by TLC using 9:1 CHCl₃:CH₃OH solvent system. After cooling to room temperature the reaction mixture was poured into crushed ice and the mixtures was stirred for 1 hours. Separated product was collected by filtration, washed with water, dried and recrystallized from aqueous

ethanol. The colors of the compounds were yellowish to dark orange and are soluble in polar organic solvents like methanol, ethanol and pyridine. The synthetic route is shown in Scheme 1. Yield was in the range of 55-68%.

General microwave assisted procedure for the synthesis of pyrimidinone substituted quinazolinone derivatives 6a-6j

Appropriate hydrazono compound **5a-5j** (0.01 mol), urea (0.015 mol), anhydrous sodium acetate (0.001 mol) and 2 ml ethanol were taken in a two-neck round bottomed flask fitted with a device condenser. The mixture was then heated under microwave irradiation at 350 W for 3-5 minutes. After cooling to room temperature the reaction mixture was poured into crushed ice and the mixtures was stirred for 30 minutes. Separated product was collected by filtration, washed with water, dried and recrystallized from aqueous ethanol. The colors of the compounds were yellowish to dark orange and are soluble in polar organic solvents like methanol, ethanol and pyridine. Yield was in the range of 71-83%.

4-[N'-(4,6-Dimethyl-2-oxo-2H-pyrimidin-5-ylidene)hydrazino]-N-(2-methyl-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide (6a)

Off white solid (Yield 76%).Mp: 145-147°C. IR (KBr): 3108 (C-H_{Ar}), 1694 (C=O), 1600 (C=N), 1339, 1156 (S=O) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.54 (s, 1H, SO₂NH), 8.70 (s, 1H, -NH-), 7.79 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.71 (td, J = 13.16, 1.52 Hz, 1H, Ar-H), 7.49 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.37 (td, J = 7.17, 1.40 Hz, 1H, Ar-H), 7.25 (dd, J = 8.64, 2.63 Hz, 2H, Ar-H), 6.44 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.43 (s, 3H, CH₃), 2.18 (s, 6H, CH₃). ¹³C NMR (400 MHz, DMSO-*d*₆) δ 172.36, 158.76, 158.10, 157.37, 155.10, 146.51, 142.63, 134.45, 130.25, 130.10, 127.17, 126.81, 123.70, 121.03, 113.06, 24.8, 23.12. MS *m/z*: 466.40 (M⁺). Anal.Calcd for C₂₁H₁₉N₇O₄S: C-54.19, H-4.11, N-21.06, S-6.89. Found: C-54.35, H-4.22, N-20.98, S-5.70.

N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6b)

Pale yellow (Yield 83%).Mp: 237-238 °C. IR (KBr): 3104 (C-H_{Ar}), 1697 (C=O), 1602 (C=N), 1336, 1154 (S=O) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.86 (s, 1H, SO₂NH), 8.77 (s, 1H, -NH-), 7.79 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.71 (td, J = 13.16, 1.52 Hz, 1H, Ar-H), 7.49 (dd, J = 7.88, 1.41 Hz, 2H, Ar-H), 7.64 (td, J = 7.17, 1.40 Hz, 1H, Ar-H), 6.67 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.20 (s, 3H, CH₃), 2.54 (s, 6H, CH₃). ¹³C NMR (400 MHz, DMSO-*d*₆) δ 171.46, 159.15, 158.62, 158.11, 152.56, 148.82, 142.34, 137.18, 131.34, 127.56, 126.21, 125.78, 123.83, 122.29, 115.11, 24.7, 23.08. MS *m/z*: 545.1 (M⁺). Anal.Calcd for C₂₁H₁₈BrN₇O₄S: C-46.33, H-3.33, N-18.01, S-5.89. Found: C-46.10, H-3.47, N-17.88, S-5.62.

N-(6,8-Dibromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-4-[N'-(4,6-dimethyl-2-oxo-2H-pyrimidin-5-ylidene)hydrazino]benzenesulfonamide (6c)

Dark yellow (Yield 79%).Mp: 180-182°C. IR (KBr): 3102 (C-H_{Ar}), 1691 (C=O), 1598 (C=N), 1340, 1156 (S=O) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.74 (s, 1H, SO₂NH), 8.83 (s, 1H, -NH-), 8.32 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 8.01 (td, J = 13.16, 1.52 Hz, 1H, Ar-H), 7.29 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.37 (td, J = 7.17, 1.40 Hz, 1H, Ar-H), 6.78 (dd, J = 8.64, 2.63 Hz, 2H, Ar-H), 2.48 (s, 3H, CH₃), 2.19 (s, 6H, CH₃). ¹³C NMR (400 MHz, DMSO-*d*₆) δ 172.55, 162.17, 159.45, 157.76, 152.57, 151.62, 143.67, 138.32, 133.67, 131.29, 127.42, 125.10,

119.21, 113.87, 112.13, 24.04, 22.88. MS *m/z*: 623 (M^+). Anal. Calcd for $C_{21}H_{17}Br_2N_4O_4S$: C-40.47, H-2.75, N-15.73, S-5.14. Found: C-40.29, H-2.54, N-15.88, S-5.25.

4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)-N-(2-methyl-6-nitro-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide (6d)

Bright yellow (Yield 75%). Mp: 194-195°C. IR (KBr): 3110 ($C-H_{Ar}$), 1690 ($C=O$), 1594 ($C=N$), 1335, 1154 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.79 (s, 1H, SO_2NH), 8.78 (s, 1H, -NH-), 8.67 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.83 (td, J = 13.16, 1.52 Hz, 1H, Ar-H), 7.49 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.37 (td, J = 7.17, 1.40 Hz, 1H, Ar-H), 7.42 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.87 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.48 (s, 3H, CH_3), 2.23 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 171.32, 159.11, 159.11, 158.93, 156.43, 154.88, 152.21, 144.67, 141.21, 132.65, 130.21, 127.43, 125.76, 123.47, 121.51, 113.11, 24.10, 22.83. MS *m/z*: 511 (M^+). Anal. Calcd for $C_{21}H_{18}N_8O_6S$: C-49.41, H-3.55, N-21.95, S-6.28. Found: C-49.22, H-3.31, N-22.09, S-6.47.

4-[N'-(4,6-Dimethyl-2-oxo-2H-pyrimidin-5-ylidene)hydrazino]-N-(4-oxo-2-phenyl-4H-quinazolin-3-yl)benzenesulfonamide (6e)

Cream solid (Yield 72%). Mp: 177-179°C. IR (KBr): 3103 ($C-H_{Ar}$), 1689 ($C=O$), 1601 ($C=N$), 1337, 1153 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.32 (s, 1H, SO_2NH), 8.34 (s, 1H, -NH-), 7.75 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.45 (m, 4H, Ar-H), 7.38 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.37 (m, 5H, Ar-H), 7.17 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.31 (dd, J = 10.68, 2.14 Hz, 1H, Ar-H), 2.09 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 169.12, 161.57, 157.87, 153.38, 152.39, 149.24, 139.22, 137.22, 132.45, 131.45, 130.27, 129.71, 127.21, 126.77, 126.02, 125.66, 123.42, 122.21, 115.18, 23.12. MS *m/z*: 528 (M^+). Anal. Calcd for $C_{26}H_{21}N_7O_4S$: C-59.19, H-4.01, N-18.59, S-6.08. Found: C-58.87, H-4.26, N-18.43, S-6.17.

N-(6-bromo-4-oxo-2-phenylquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6f)

Light yellow (Yield 80%). Mp: 192-193°C. IR (KBr): 3112 ($C-H_{Ar}$), 1698 ($C=O$), 1605 ($C=N$), 1332, 1152 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.41 (s, 1H, SO_2NH), 8.37 (s, 1H, -NH-), 7.71 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.39 (m, 4H, Ar-H), 7.31 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.15 (m, 4H, Ar-H), 6.69 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.44 (dd, J = 10.68, 2.14 Hz, 1H, Ar-H), 2.11 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 171.45, 163.54, 157.76, 155.53, 153.83, 148.33, 143.71, 139.46, 135.17, 132.56, 131.65, 130.45, 129.67, 129.14, 125.76, 124.32, 123.88, 117.78, 113.95, 23.07. MS *m/z*: 607 (M^+). Anal. Calcd for $C_{26}H_{20}BrN_7O_4S$: C-51.49, H-3.32, N-16.17, S-5.29. Found: C-51.31, H-3.07, N-16.41, S-5.35.

N-(6,8-dibromo-4-oxo-2-phenylquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6g)

Brownish yellow (Yield 77%). Mp: 209-211°C. IR (KBr): 3105 ($C-H_{Ar}$), 1694 ($C=O$), 1595 ($C=N$), 1334, 1151 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.37 (s, 1H, SO_2NH), 8.30 (s, 1H, -NH-), 7.63 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.57 (m, 3H, Ar-H), 7.34 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 6.99 (m, 3H, Ar-H), 6.54 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.36 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.21 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 173.42, 162.74, 160.47, 158.87, 153.78, 152.32, 143.12, 137.32, 134.01, 132.65, 131.48, 130.37, 127.47, 129.54, 125.51, 124.91, 118.56, 115.11, 110.23, 23.05. MS *m/z*: 686 (M^+). Anal.

Calcd for $C_{26}H_{19}Br_2N_7O_4S$: C-45.57, H-2.79, N-14.31, S-4.68. Found: C-45.35, H-2.96, N-14.18, S-4.77.

N-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6h)

Creamy white solid (Yield 71%). Mp: 215-217°C. IR (KBr): 3113 ($C-H_{Ar}$), 1688 ($C=O$), 1603 ($C=N$), 1329, 1158 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.41 (s, 1H, SO_2NH), 8.25 (s, 1H, -NH-), 7.81 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.45 (m, 3H, Ar-H), 7.37 (dd, J = 7.88, 1.41 Hz, 1H, Ar-H), 7.22 (d, J = 7.88 Hz, 2H, Ar-H), 6.82 (d, J = 7.88 Hz, 2H, Ar-H), 6.70 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.38 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.17 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 173.32, 164.58, 155.11, 153.65, 152.85, 149.75, 144.65, 137.83, 136.27, 132.17, 130.55, 129.41, 126.81, 126.61, 126.17, 126.02, 125.24, 122.66, 113.76, 23.19. MS *m/z*: 563 (M^+). Anal. Calcd for $C_{26}H_{20}ClN_7O_4S$: C-55.57, H-3.59, N-17.45, S-5.71. Found: C-55.29, H-3.68, N-17.27, S-5.53.

N-(6-bromo-2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6i)

Pale yellow (Yield 79%). Mp: 188-190°C. IR (KBr): 3104 ($C-H_{Ar}$), 1698 ($C=O$), 1606 ($C=N$), 1337, 1155 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.47 (s, 1H, SO_2NH), 8.31 (s, 1H, -NH-), 7.83 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.49 (m, 3H, Ar-H), 7.38 (d, J = 7.88 Hz, 1H, Ar-H), 7.26 (d, J = 7.88 Hz, 2H, Ar-H), 6.85 (d, J = 7.88 Hz, 1H, Ar-H), 6.72 (dd, J = 8.64, 2.63 Hz, 1H, Ar-H), 6.41 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.18 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 172.67, 161.32, 159.11, 155.41, 152.35, 147.63, 142.14, 137.51, 136.71, 135.57, 134.17, 132.43, 130.64, 129.56, 126.33, 125.81, 123.09, 114.12, 113.59, 23.22. MS *m/z*: 641 (M^+). Anal. Calcd for $C_{26}H_{19}BrClN_7O_4S$: C-48.73, H-2.99, N-15.30, S-5.00. Found: C-48.56, H-2.73, N-15.42, S-5.17.

N-(6,8-dibromo-2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-4-(2-(4,6-dimethyl-2-oxopyrimidin-5(2H)-ylidene)hydrazinyl)benzenesulfonamide (6j)

Yellowish orange (Yield 81%). Mp: 224-225°C. IR (KBr): 3110 ($C-H_{Ar}$), 1699 ($C=O$), 1603 ($C=N$), 1338, 1154 ($S=O$) cm^{-1} . 1H NMR (400 MHz, $DMSO-d_6$) δ 10.45 (s, 1H, SO_2NH), 8.27 (s, 1H, -NH-), 7.82 (dd, J = 7.71, 1.56 Hz, 1H, Ar-H), 7.52 (m, 3H, Ar-H), 7.39 (d, J = 7.88 Hz, 1H, Ar-H), 7.24 (d, J = 7.88 Hz, 2H, Ar-H), 6.86 (d, J = 7.88 Hz, 1H, Ar-H), 6.36 (dd, J = 10.68, 2.14 Hz, 2H, Ar-H), 2.21 (s, 6H, CH_3). ^{13}C NMR (400 MHz, $DMSO-d_6$) δ 171.78, 162.84, 160.78, 157.72, 154.35, 152.51, 143.56, 137.78, 136.32, 132.21, 133.17, 132.45, 131.42, 130.77, 128.21, 124.43, 117.69, 116.21, 110.18, 23.12. MS *m/z*: 720 (M^+). Anal. Calcd for $C_{26}H_{18}Br_2ClN_7O_4S$: C-43.38, H-2.52, N-13.62, S-4.45. Found: C-43.22, H-2.71, N-13.48, S-4.60.

In vitro antimicrobial studies

All the synthesized compounds were screened for their *in vitro* antimicrobial activities against selected pathogenic bacterial strains to determine minimum inhibitory concentrations (MIC) by broth micro dilution method [27] using Sulfanilamide as reference drugs of parent moieties, while Streptomycin was employed as a standard antibacterial drug.

The *in vitro* antimicrobial activities of all the synthesized compounds were screened for their antibacterial against *Staphylococcus aureus*, *Bacillus subtilis*, *Bacillus megaterium* (Gram Positive) and *Escherichia coli*, *Proteus vulgaris*, *Pseudomonas aeruginosa* (Gram

Compound	Minimum Inhibition Concentration in µg/mL					
	Gram positive bacteria			Gram negative bacteria		
	<i>B. megaterium</i>	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>P. vulgaris</i>	<i>P. aeruginosa</i>
6a	300	200	300	225	200	250
6b	375	350	350	300	225	350
6c	400	395	400	250	300	420
6d	375	400	350	300	275	350
6e	225	200	225	175	200	225
6f	300	300	275	225	225	225
6g	250	200	225	225	250	200
6h	175	125	150	50	50	75
6i	200	175	200	75	50	150
6j	200	150	100	100	75	100
Sf*	425	375	400	375	400	425
Sm*	20	20	20	20	20	20

*Sf= Sulfanilamide, Sm = Streptomycin

Table 1: Antimicrobial activities of the synthesized compounds 6a-6j.

Negative), using the broth dilution method [27]. All the ATCC culture was collected from institute of microbial technology, Bangalore. 2% Luria broth solution was prepared in distilled water while, pH of the solution was adjusted to 7.4 ± 0.2 at room temperature and sterilized by autoclaving at 15 lb pressure for 25 min. The tested bacterial and fungal strains were prepared in the luria broth and incubated at 37°C and 200 rpm in an orbital incubator for overnight. Sample solutions were prepared in DMSO for various concentration. The standard drug solution of Streptomycin (antibacterial drug) was prepared in DMSO. Serial broth micro dilution was adopted as a reference method. 10 µL solution of test compound was inoculated in 5 mL luria broth for each concentration respectively and additionally one test tubes was kept as control. Each of the test tubes was inoculated with a suspension of standard microorganism to be tested and incubated at 35°C for 24 h. At the end of the incubation period, the tubes were examined for the turbidity. Turbidity in the test tubes indicated that microorganism growth has not inhibited by the antibiotic contained in the medium at the test concentration. The antimicrobial activity tests were performed in triplicate and the deviation for any triplicate results was not more than $\pm 1\%$ to 5% while average MIC values of the compounds are represented in Table 1.

Results and Discussion

The intention of the present study was to synthesize and investigate the antimicrobial activities of pyrimidinone ring substituted at 3rd position of quinazolinone derivatives (6a-6j) through hydrazono benzenesulfonamide linkage in a single molecular frame work. Synthetic rout of the target molecules is outlined in the Scheme 1 under both conventional and microwave heating condition. When cyclization for the formation of pyrimidinone derivatives was performed under microwave irradiation, the reaction was taken place in 3 minutes in an improved yield.

All the synthesized compounds were characterized by their physical, analytical and spectral properties. The IR, ESI-MS and NMR (¹H and ¹³C) spectral data of all the synthesized compounds were in good agreement with the structure assigned. Further, in the MS-ESI with positive mode spectra exhibited molecular ion peak ([M+H]⁺), appeared at different intensities, confirmed the exact mass or molecular weights of the examined compounds 6a-6j, while appearance of a characteristic two isotope peak ([M+H]⁺²) along with molecular ion peak ([M+H]⁺) in an intense ratio almost 3:1 or 1:1 to the molecular ion peak confirmed the presence of halogen (Cl or Br) atoms of high

abundance nature. The IR spectrum of 6a-6j showed the presence of C=O group at ~1690 cm⁻¹ due to -CONH and -COCH₃ groups. Two sharp bands at ~1340 and ~1160 cm⁻¹ were due to asymmetric and symmetric stretching vibrations of SO₂ group respectively. The ¹H NMR of entitled compounds 6a-6j showed singlet around $\delta \sim 10.50$ ppm due to highly deshielded proton of -NHSO₂ group. One singlet was observed about $\delta \sim 8.77$ ppm due to secondary amine group. The two more singlet appeared in the aliphatic region at δ 2.43 and 2.18 ppm due to -CH₃ (second position of the quinazolinone ring) and -CH₃ (two methyl group of pyrimidinone ring) protons. All the eight aromatic protons resonated in the region of δ 7.79 to 6.44 ppm. The ¹³C NMR of final compounds 6a-6j showed two signals of carbonyl carbon around $\delta \sim 170$ (CO of pyrimidinone ring), ~ 160 (CO of quinazolinone ring). The aromatic carbons appeared between δ 113-158 ppm. The signals due to aliphatic carbons appeared about ~ 24 and ~ 22.5 due to presence of two different methyl groups in quinazolinone ring and pyrimidinone ring.

In vitro antimicrobial activities

Inspection of the data of Table 1, on the preliminary *in vitro* antimicrobial evaluations of the entitled compounds 6a-6j revealed that all the screened compounds have a varied degree of antibacterial activity, evident from their MIC values in µg/mL. Among the screened compounds, most of the compounds have shown more or equal antimicrobial activities compare to the reference drug Sulfanilamide (Sf), while a very few of the screened compounds found to be equipotent to the standard drugs, Streptomycin (Sm). From the results of *in vitro* antibacterial activity data, it was observed that compounds 6e, 6h, 6i and 6j demonstrated excellent activity against *E. coli* and *P. vulgaris* bacterial species. In general, compounds showed more selectivity against Gram negative over Gram positive species amongst all the bacterial strains. All the compounds were screened for their *in vitro* antimicrobial activities and results revealed that the group 4-chlorophenyl substitution at the 2nd position in quinazolin-4(3H)-one nucleus led to increase their biological activities.

Conclusion

In summary, a series of new pyrimidinone substituted Quinazolin-4(3H)-one derivatives have been synthesized by adapting a simple and facile manner using both conventional and microwave heating condition in a good amount of yields. All the compounds were screened for their *in vitro* antimicrobial activity and results revealed

that compounds 6e, 6h, 6i and 6j demonstrated excellent activity against *E. coli* and *P. vulgaris* bacterial species.

Acknowledgements

We are thankful to the Principal, V. P. & R. P. T. P. Science College, VallabhVidyanagar for providing necessary research facilities. We are also grateful to SICART, VallabhVidyanagar for FT-IR and Mass analysis; CDRI, Lucknow for NMR analyses.

References

1. Li LH, Wallace TL, Wierenga W, Skulnick HI, DeKoning TF (1987) Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers. *J Biol Response Mod* 6: 44-55.
2. Li LH, Wallace TL, Hamilton RD, DeKoning TF (1987) Pharmacological evaluation of combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones. *Int J Immunopharmacol* 9: 31-39.
3. Eggermont AM, Marquet RL, De Bruin RW, Weimar W, Jeekel J (1986) Site-specific antitumor effects of 2-pyrimidinone compounds in rats. *Br J Cancer* 54(2): 337-339.
4. Li LH, Johnson MA, Moeller RB, Wallace TL (1984) Chemotherapy of B16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones. *Cancer Res* 44: 2841-2847.
5. Li LH, Wallace TL, Richard KA, Tracey DE (1985) Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia. *Cancer Res* 45: 532-538.
6. Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, et al. (1991) Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. *J Med Chem* 34: 3280-3284.
7. Li LH, DeKoning TF, Nicholas JA, Kramer GD, Wilson D, et al. (1987) Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones. *Lab Anim Sci* 37: 41-44.
8. Rashad AE, Shamroukh AH, Yousif NM, Salama MA, Ali HS, et al. (2012) New pyrimidinone and fused pyrimidinone derivatives as potential anticancer chemotherapeutics. *Archiv der Pharmazie* 345: 729-738.
9. Holla BS, Rao BS, Sarojini BK, Akberali PM (2004) One pot synthesis of thiazolidinopyrimidinones and evaluation of their anticancer activity. *Eur J Med Chem* 9: 777-783.
10. Zhang X, Glunz PW, Jiang W, Schmitt A, Newman M, et al. (2013) Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors. *Bioorg Med Chem Lett* 23: 1604-1607.
11. Paul JH, Alan JW, Geoffrey SB, Sharon MK, Jonathan PW, et al. (1999) Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. *J Mol Bio* 286: 389-401.
12. Aly MM, Mohamed YA, El-Bayouki KA, Basyouni WM, Abbas SY (2010) Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and antimicrobial activities - part-1. *Eur J Med Chem* 45: 3365-3373.
13. Kidwai M, Saxena S, Khan MKR, Thukral SS (2005) Synthesis of 4-aryl-7,7-dimethyl-1,2,3,4,5,6,7,8-octahydroquinazolin-2-one/thione-5-one derivatives and evaluation as antibacterials. *Eur J Med Chem* 40: 816-819.
14. Dahiya R, Kumar A (2008) Synthesis and biological activity of peptide derivatives of iodoquinazolinones/nitroimidazoles. *Molecules* 13: 958-976.
15. El-Azab AS, Al-Omar MA, Sayed-Ahmed MM, Abdel-Hamide SG (2010) Design, synthesis and biological evaluation of novel quinazolinone derivatives as potential antitumor agents: molecular docking study. *Eur J Med Chem* 45: 4188-4198.
16. Giri RS, Thaker HM, Giordano T, Chen B, Vasu KK (2010) Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-kappaB, AP-1 mediated transcription and eIF-4E mediated translational activation: inhibitors of multi-pathways involve in cancer. *Eur J Med Chem* 45: 3558-3563.
17. Kumar A, Rajput CS (2009) Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives. *Eur J Med Chem* 44: 83-90.
18. Kashaw SK, Kashaw V, Mishra P, Jain NK, Stables JP (2009) Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenylethyl-4H-quinazolin-3-yl)-urea. *Eur J Med Chem* 44: 4335-4343.
19. Ghorab MM, Gawad SMA, El-Gaby MS (2000) Synthesis and evaluation of some new fluorinated hydroquinazolinone derivatives as antifungal agents. *Farmacol* 55: 249-255.
20. Mei H, Chun C (2009) Three-component one-pot synthesis of pyrimidinone derivatives in fluorosol media: Ytterbium bis(perfluorooctanesulfonyl)imide complex catalyzed Biginelli-type reaction. *J Het Chem* 46: 1430-1432.
21. Hossain ASM, Abu-Melha HMA, Al-Omar MA, Amr AEGE (2012) Synthesis and antimicrobial activity of some new pyrimidinone and oxazinone derivatives fused with thiophene rings using 2-chloro-6-ethoxy-4-acetylpyridine as starting material. *Molecules* 17: 13642-13655.
22. Jagani CL, Sojitra NA, Vanparia SF, Patel TS, Dixit RB, Dixit BC (2011) A comparative study of solution phase as well as solvent free microwave assisted syntheses of 3-benzothiazole/isoxazole substituted 2-styryl-4(3H)-quinazolinones. *ARKIVOC* ix: 281-294.
23. Sojitra NA, Dixit RB, Patel RK, Patel JP, Dixit BC (2012) Classical and microwave assisted synthesis of new-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylazo)-N-(2-substituted-4-oxo-4H-quinazolin-3-yl)benzenesulfonamide derivatives and their antimicrobial activities. *J Saudi Chem Soc*.
24. Vogel AI (2004) *A Textbook of Practical Organic Chemistry*. (5th edn) Singapore.
25. Dixit BC, Patel HM, Dixit RB, Desai DJ (2010) Synthesis, characterization and dyeing assessment of novel acid azo dyes and mordant acid azo dyes based on 2-hydroxy-4-methoxybenzophenone on wool and silk fabrics. *J Serb Chem Soc* 75: 605-614.
26. Singh SP, Parmar SS, Raman K, Stenberg VI (1981) Chemistry and biological activity of thiazolidinones. *Chem Rev* 81: 175-203.
27. Jani DH, Patel HS, Keharia H, Modi CH (2010) Novel drug-based Fe(III) heterochelates: synthetic, spectroscopic, thermal and in-vitro antibacterial significance *Appl Organometal Chem* 24: 99-111.

Citation: Sojitra NA, Patel RK, Dixit RB, Dixit BC (2013) Synthesis and Antimicrobial Study of Pyrimidinone Substituted 4(3H)-Quinazolinone Derivatives. *Organic Chem Curr Res* 2: 118. doi:10.4172/2161-0401.1000118

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscripts as E-mail: editor.organicchemistry@omicsonline.org